Comparative Pharmacology
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus FLUVASTATIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus FLUVASTATIN SODIUM.
ATORVASTATIN CALCIUM vs FLUVASTATIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased intracellular cholesterol levels and upregulation of LDL receptors.
10-80 mg orally once daily, starting at 10-20 mg; maximum dose 80 mg/day.
20 to 80 mg orally once daily in the evening; immediate-release: 20-40 mg once daily; extended-release: 80 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 11–24 h); the active metabolite half-life is 20–30 h; clinical context: supports once-daily dosing despite shorter HMG-CoA reductase inhibitory half-life due to prolonged pharmacodynamic effect.
The terminal elimination half-life is 2.3 hours (range 1.4–3.1 hours). Due to its short half-life, it is dosed once daily for sustained HMG-CoA reductase inhibition; however, pharmacodynamic effects (LDL reduction) persist beyond plasma clearance.
Primarily biliary excretion (approx. 70%) as metabolites; renal excretion accounts for <2% of the administered dose; fecal elimination of metabolites and parent drug (approx. 90%).
Fluvastatin sodium is primarily eliminated via biliary/fecal excretion (approximately 90%), with renal excretion accounting for less than 6% of the administered dose.
Category C
Category D/X
Statin
Statin